ÇERKEZKÖY 1 MANUFACTURING SITE
DEVA Holding Çerkezköy-I Manufacturing Facility, located approximately at a 100 km distance to Istanbul, is founded on an area of 52,000 m2 in Çerkezköy Organized Industrial Zone with closed facilities of 32,000 m2. The facility comprises of modern buildings where liquids/semi-solids and solids, cephalosporin, penicillin, hormone-containing products, inhaled products, sterile liquid ampoules and vials, and soft gel capsules are manufactured.
 

In the production facility, a total of 141 million units were manufactured in 2018 compared to 153 million units in 2019.

Liquid / Semi Solid and Solids Manufacturing Area

In the liquid and semi-solid area, syrup-drop and spray, creams and gels, suppository and pessary-form products are manufactured using the state-of-art technology.

In the unit, in which a total of 28.8 million units were manufactured in 2018, a total of 25 million units were manufactured in 2019.



In the solids unit, tablets and film coated tablets, capsules and powder suspensions-form drugs are manufactured using the state-of-art technology.

In this unit, in which 48.9 million units products were manufactured in 2018, a total of 58.9 million units were manufactured in 2019, of which 56.1 million units were tablets/soft gel capsules, and 2.8 million units were suspensions.

There has been a 20% increase in the solids unit’s production in 2019 compared with 2018.



Cephalosporin Manufacturing Area (Betalactam I)

Whereas, in the cephalosporin, 27.2 million units were manufactured in 2018, a total of 27 million units of pharmaceutical products were manufactured in 2019; 23 million units of injectable sterile powder vials, 1.4 million units of oral suspensions, and 2.6 million units of film-coated tablets and capsules.


Penicillin Manufacturing Area (Betalactam II)

Whereas, in the penicillin area, 17.3 million unitswere manufactured in 2018, a total of 18.8 million units of pharmaceutical products were manufactured in 2019; 7.8 million units of injectable sterile powder vials, 4.2 million units of oral suspensions, and 6.8 million unitsof film-coated tablets.

 

There has been a 9% increase in the penicillin area’s production in 2019 compared with 2018.



Hormone Products Manufacturing Area

Whereas, in the hormone products unit, 15.3 million units of products were manufactured in 2018; approximately 18.6 million units or product were manufactured in 2019; 3.2 million units of creams/pomades, 2.5 million units of solid tablets and film-coated tablets, and 12.9 million units of sterile ampoules, vials, and drops.

There was a 22% increase in hormone production in 2019 compared to 2018.



Inhaled Products Manufacturing Area

Approved by the Ministry of Health in 2014, the facility has its own ventilation, water system and laboratory in a separate building. 2.6 million unitsof MDI and DPI were manufactured in 2018 compared with 3.5 million units in 2019.

 

There has been a 34% increase in the inhaler unit’s production in 2019 compared with 2018..

Sterile Liquid Ampoule and Vial and Soft Gel Capsule Products Manufacturing Area

In the Sterile Liquid Ampoule and Vial unit, 1.5 million units of sterile vials were manufactured in 2018, while 1.1 million units of vials were manufactured in 2019.